Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model

Journal of Immunology

Volumn 185, Issue 4, 2010, Pages 2580-2588

  Bourquin, Carole ^a   Von Der Borch, Philip ^a   Zoglmeier, Christine ^a   Anz, David ^a   Sandholzer, Nadja ^a   Suhartha, Nina ^a   Wurzenberger, Cornelia ^a   Denzel, Angela ^a   Kammerer, Robert ^a,b   Zimmermann, Wolfgang ^a   Endres, Stefan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; HYBRID PROTEIN; OLIGONUCLEOTIDE; VIRUS T ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CANCER THERAPY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ERADICATION THERAPY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40; SPLEEN CELL; STOMACH CANCER; STOMACH TUMOR; T LYMPHOCYTE; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; VACCINATION; WILD TYPE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CPG ISLAND; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOLOGY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROMOTER REGION; SPLEEN; SURVIVAL; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CPG ISLANDS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGONUCLEOTIDES; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; SPLEEN; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINATION;

EID: 77956922166     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903231     Document Type: Article

References (42)

1. Parkin, D. M., F. Bray, J. Ferlay, and P. Pisani. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108.
2. Ajisaka, H., and K. Miwa. 2003. Micrometastases in sentinel nodes of gastric cancer. Br. J. Cancer 89: 676-680.
3. Oba, K., S. Teramukai, M. Kobayashi, T. Matsui, Y. Kodera, and J. Sakamoto. 2007. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol. Immunother. 56: 905-911.
4. Jeung, H. C., Y. W. Moon, S. Y. Rha, N. C. Yoo, J. K. Roh, S. H. Noh, J. S. Min, B. S. Kim, and H. C. Chung. 2008. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann. Oncol. 19: 520-526.
5. Kono, K., A. Takahashi, H. Sugai, H. Fujii, A. R. Choudhury, R. Kiessling, and Y. Matsumoto. 2002. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin. Cancer Res. 8: 3394-3400.
6. Sato, Y., H. Shomura, Y. Maeda, T. Mine, Y. Une, Y. Akasaka, M. Kondo, S. Takahashi, T. Shinohara, K. Katagiri, et al. 2003. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci. 94: 802-808.
7. + T-cell infiltration and high microvessel density in patients with gastric cancer. Int. J. Cancer 118: 1909-1914.
8. Romano, F., G. Cesana, R. Caprotti, G. Bovo, F. Uggeri, M. G. Piacentini, S. Crippa, and F. Uggeri. 2006. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients. Hepatogastroenterology 53: 634-638.
9. + T cells and natural killer cells in gastric adenocarcinoma. Ann. Surg. Oncol. 15: 1775-1782.
10. Thompson, J., T. Epting, G. Schwarzkopf, A. Singhofen, A. M. Eades-Perner, H. van Der Putten, and W. Zimmermann. 2000. A transgenic mouse line that develops early-onset invasive gastric carcinoma provides a model for carcinoembryonic antigen-targeted tumor therapy. Int. J. Cancer 86: 863-869. (Pubitemid 30350203)
11. Nöckel, J., N. K. van den Engel, H. Winter, R. A. Hatz, W. Zimmermann, and R. Kammerer. 2006. Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 T antigen-transgenic mice with or without a human CEA transgene. BMC Cancer 6: 57.
12. Corbett, T. H., B. J. Roberts, W. R. Leopold, J. C. Peckham, L. J. Wilkoff, D. P. Griswold, Jr., and F. M. Schabel, Jr. 1984. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 44: 717-726.
13. Corbett, T. H., D. P. Griswold, Jr., B. J. Roberts, J. C. Peckham, and F. M. Schabel, Jr. 1975. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35: 2434-2439.
14. Brunner, C., J. Seiderer, A. Schlamp, M. Bidlingmaier, A. Eigler, W. Haimerl, H. A. Lehr, A. M. Krieg, G. Hartmann, and S. Endres. 2000. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J. Immunol. 165: 6278-6286.
15. Heckelsmiller, K., S. Beck, K. Rall, B. Sipos, A. Schlamp, E. Tuma, S. Rothenfusser, S. Endres, and G. Hartmann. 2002. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 32: 3235-3245.
16. Wurzenberger, C., V. H. Koelzer, S. Schreiber, D. Anz, A. M. Vollmar, M. Schnurr, S. Endres, and C. Bourquin. 2009. Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo. Cancer Immunol. Immunother. 58: 901-913.
17. Heckelsmiller, K., K. Rall, S. Beck, A. Schlamp, J. Seiderer, B. Jahrsdörfer, A. Krug, S. Rothenfusser, S. Endres, and G. Hartmann. 2002. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169: 3892-3899.
18. Ballas, Z. K., A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner. 2001. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167: 4878-4886.
19. Raghavan, S., J. Nyström, M. Fredriksson, J. Holmgren, and A. M. Harandi. 2003. Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection. Infect. Immun. 71: 7014-7022.
20. Yu, P., D. A. Rowley, Y. X. Fu, and H. Schreiber. 2006. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr. Opin. Immunol. 18: 226-231.
21. Sawanobori, Y., S. Ueha, M. Kurachi, T. Shimaoka, J. E. Talmadge, J. Abe, Y. Shono, M. Kitabatake, K. Kakimi, N. Mukaida, and K. Matsushima. 2008. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111: 5457-5466.
22. Ostrand-Rosenberg, S. 2004. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. Opin. Immunol. 16: 143-150.
23. Schreiber, K., D. A. Rowley, G. Riethmüller, and H. Schreiber. 2006. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol. Oncol. Clin. North Am. 20: 567-584.
24. Nguyen, L. T., A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi. 2002. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195: 423-435.
25. Schell, T. D., L. M. Mylin, I. Georgoff, A. K. Teresky, A. J. Levine, and S. S. Tevethia. 1999. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J. Virol. 73: 5981-5993.
26. Ye, X., J. McCarrick, L. Jewett, and B. B. Knowles. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA 91: 3916-3920.
27. Zheng, X., J. X. Gao, H. Zhang, T. L. Geiger, Y. Liu, and P. Zheng. 2002. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J. Immunol. 169: 4761-4769.
28. Belnoue, E., C. Guettier, M. Kayibanda, S. Le Rond, A. M. Crain-Denoyelle, C. Marchiol, M. Ziol, D. Fradelizi, L. Rénia, and M. Viguier. 2004. Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy. J. Immunol. 173: 4882-4888.
29. Garbi, N., B. Arnold, S. Gordon, G. J. Hämmerling, and R. Ganss. 2004. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172: 5861-5869.
30. + T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J. Immunol. 177: 3089-3099.
31. + T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J. Immunol. 161: 5133-5137.
32. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G. J. Hämmerling. 2002. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62: 1462-1470.
33. + T cells. J. Immunol. 180: 3122-3131.
34. Gray, A., A. B. Raff, M. Chiriva-Internati, S. Y. Chen, and W. M. Kast. 2008. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol. Rev. 222: 316-327.
35. Buckanovich, R. J., A. Facciabene, S. Kim, F. Benencia, D. Sasaroli, K. Balint, D. Katsaros, A. O'Brien-Jenkins, P. A. Gimotty, and G. Coukos. 2008. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14: 28-36.
36. Verdeil, G., K. Marquardt, C. D. Surh, and L. A. Sherman. 2008. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc. Natl. Acad. Sci. USA 105: 16683-16688.
37. Hamzah, J., M. Jugold, F. Kiessling, P. Rigby, M. Manzur, H. H. Marti, T. Rabie, S. Kaden, H. J. Gröne, G. J. Hämmerling, et al. 2008. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453: 410-414.
38. Macpherson, A. J., and K. Smith. 2006. Mesenteric lymph nodes at the center of immune anatomy. J. Exp. Med. 203: 497-500.
39. Djafarzadeh, R., E. Noessner, H. Engelmann, D. J. Schendel, M. Notohamiprodjo, I. von Luettichau, and P. J. Nelson. 2006. GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene 25: 1496-1508.
40. Anz, D., V. H. Koelzer, S. Moder, R. Thaler, T. Schwerd, K. Lahl, T. Sparwasser, R. Besch, H. Poeck, V. Hornung, et al. 2010. Immunostimulatory RNA blocks suppression by regulatory T cells. J. Immunol. 184: 939-946.
41. Hamzah, J., D. Nelson, G. Moldenhauer, B. Arnold, G. J. Hämmerling, and R. Ganss. 2008. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest. 118: 1691-1699.
42. Aouadi, M., G. J. Tesz, S. M. Nicoloro, M. Wang, M. Chouinard, E. Soto, G. R. Ostroff, and M. P. Czech. 2009. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458: 1180-1184.